Ponizej przeklejam fragment postu Kinaszle z linkiem do artykulu na temat IADT.
Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
Published online 2018 Aug 2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080876/
Konkluzje artykułu:
W przypadku mężczyzn we wczesnych stadiach PCA nie można sformułować żadnych zaleceń dotyczących preferowanego stosowania IADT (przerywanej) lub CADT (ciągłej) ze względu na brak dostępnych dowodów.
W przypadku mężczyzn w zaawansowanym stadium choroby należy rozważyć IADT, gdy tylko będzie to uzasadnione klinicznie (słabe zalecenie i mała pewność dowodów). Lekarze powinni omówić ryzyko i korzyści IADT i CADT z pacjentami, biorąc pod uwagę ich wartości i preferencje.
I pdf artykulu (wg mnie latwiejszy do chomikowania):
_____________Edit 06.2019 -zb_____________________
Ponizej wybrane opracowania, do ktorych odnosi się zacytowany artykul:
References
3. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(Suppl 5):S37–S43. [PMC free article] [PubMed] [Google Scholar]
5. Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer. 2013;108(1):9–13. [PMC free article] [PubMed] [Google Scholar]
6. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465–471. [PMC free article] [PubMed] [Google Scholar]
7. Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–192. [PMC free article] [PubMed] [Google Scholar]
8. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–709. [PubMed] [Google Scholar]
10. Krahn MD, Bremner KE, Luo J, Alibhai SM. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol. 2014;21(3):e457–e465. [PMC free article] [PubMed] [Google Scholar]
11. Tunn UW, Canepa G, Kochanowsky A, Kienle E. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2012;15(3):296–302. [PubMed] [Google Scholar]
21. Magnan S, Zarychanski R, Pilote L, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1(9):1261–1269. [PubMed] [Google Scholar]
22. Schulman C, Cornel E, Matveev V, et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (Iceland) Eur Urol. 2016;69(4):720–727. [PubMed] [Google Scholar]
23. Crawford D, Shore N, Higano CS, Neijber A, Yankov V. Intermittent androgen deprivation with the gonadotrophin releasing hormone antagonist degarelix. J Urol. 2014;191(4 Suppl 1):e766. [Google Scholar]
24. Casas F, Henriquez I, Bejar A, et al. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Transl Oncol. 2017;19(3):373–378. [PubMed] [Google Scholar]
25. Chun-Leung Chau D, Wang D, Tedesco A, et al. Prostate cancer patients’ preferences for intermittent vs. continuous androgen deprivation— a pilot institutional study. J Med Imaging Radiat Sci. 2016;47(1):108–112. e102. [Google Scholar]
26. Crawford D, Shore N, Higano CS, Neijber A, Yankov V. Intermittent androgen deprivation with the GnRH antagonist degarelix in men with biochemical relapse of prostate cancer. Am J Hematol Oncol. 2015;11(12):6–13. [Google Scholar]
27. Bultijnck R, Surcel C, Ploussard G, et al. Practice patterns compared with evidence-based strategies for the management of androgen deprivation therapy–induced side effects in prostate cancer patients: results of a European web-based survey. Eur Urol Focus. 2016;2(5):514–521. [PubMed] [Google Scholar]
28. Liede A, Hallett DC, Hope K, Graham A, Arellano J, Shahinian VB. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open. 2016;1(2):e000040. [PMC free article] [PubMed] [Google Scholar]